Paxlovid may offer marginal benefits for low-risk children with COVID-19; however, among high-risk children with COVID-19, Paxlovid is a safe oral option.

Using glucocorticoids, rituzimab, or certain immunosuppressants to treat connective tissue diseases is associated with greater risks for severe COVID-19-related outcomes.

COVID-19 vaccines were not associated with increased risk for thyroid diseases but were associated with increased risk for exacerbated hypothyroidism.